Daunorubicin is mainly used in combination with other cytotoxic drugs. Additive toxicity may occur especially with regard to bone marrow/haematologic and gastrointestinal effects (see Precautions). The use of daunorubicin in combination chemotherapy with other potentially cardiotoxic drugs, as well as the concomitant use of other cardioactive compounds (e.g., calcium channel blockers), requires monitoring of cardiac function throughout treatment. Changes in hepatic or renal function induced by concomitant therapies may affect daunorubicin metabolism, pharmacokinetics, therapeutic efficacy and/or toxicity.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign Out
